From early to exit

A steady stream of M&A during lean years and IPOs when the biotech markets heated up persuaded LPs that Sofinnova Partners' early stage investment strategy can generate exits regardless of market conditions.

The VC parlayed that sentiment into its largest life sciences fund to date last week, when it announced the close of Sofinnova Capital VIII at €300 million ($324.6 million), the fund's maximum cap and well above the initial target of €250 million ($270.5 million)...